Venous thromboembolism is one of the main causes of sudden death in hospitalized patients. Among the classical risk factors involved, cancer occupies a special place. Up to 20% of oncological patients will develop a VTE episode, and in 10% of them, it will be a direct cause of death. In the case presented below, incidental pulmonary embolism and renal tumor were diagnosed at the same time, and there was an event of embolism despite optimal antithrombotic treatment. Such a scenario of complications may correlate with a clinically advanced stage of cancer, and may be associated with a poorer prognosis, requiring an individualized therapeutic management.
INTRODUCTION
Venous thromboembolism (VTE) that takes the form of pulmonary embolism (PE) is the cause of up to 30% of sudden deaths in patients hospitalized for internal diseases, and 11% of deaths in patients treated for cancer [1] . Altogether, VTE is the second most common cause of death in cancer patients [2] . In the general population, its incidence is 100-200 cases/100.000 persons/year [3] . As for the general population, a number of VTE risk factors have been determined, making is possible to estimate the risk of PE or deep vein thrombosis (DVT). The most significant classical risk factors include: immobility, surgery, trauma, oral contraception and hormone replacement therapy. Cancer patients constitute a population that is especially exposed to the risk of VTE, and in particular those who suffer from hematological malignancies, lung cancer, gastrointestinal cancer, kidney or brain tumors, as well as those who undergo chemotherapy [4] .
VTE is often diagnosed only incidentally, when performing imaging tests aimed at diagnosing or monitoring the progression of a neoplastic disease. Up to 20% of cancer patients are affected by the condition [5] . The high VTE rates in oncological patients, and a potentially lethal course of the disease, require special diagnostic vigilance, in particular in patients with additional VTE risk factors.
CASE DESCRIPTION
A previously healthy 52-year-old patient was transferred to the Due to the patient's stable hemodynamic condition, it was decided that UFH therapy would be continued for 12 days, main- In the case presented above, abdominal CT was performed twice, without revealing enlarged lymph nodes, which does not exclude the presence of metastatic cells in them, though.
The patient received anticoagulation therapy in accordance with the binding ESC (European Society of Cardiology) standards [8] .
Nevertheless, there was a recurrent episode of pulmonary embolism, most probably as a result of migration of thrombus from deep veins. IVC filters are indicated in such cases [9] . In the above described case, a retrievable IVC filter was implanted, which may safely be removed transvenously, following a completed treatment, and with no further indications for anticoagulation therapy [10, 11] .
Prognosis of renal cell carcinoma RCC patients is assessed based on the SSIGN score (Stage, SIze, Grade and Necrosis) [12] . The patient's score was 8, which classifies her as a high-risk patient, with the estimated 5-year survival rate of 21% [13] . Oncological follow-up of the RCC patient involves chest and abdomen CT repeated every 6 months in the first 2 years, with subsequent test intervals determined on a case by case basis, depending on the patient's clinical status [12] . Following resection, median time to relapse is 1.9 years [15] .
An additional factor that directly affects patient prognosis is recurrent pulmonary embolism. In cancer patients on anticoagulation therapy the risk of recurrent pulmonary embolism or major bleeding is 3-6 times higher than in the non-cancer population [13] .
Treatment of acute VTE and chronic anticoagulation therapy is different in cancer patients from that administered in patients without malignancies. Low molecular weight heparins (LMWHs)
are preferred over the first 6 months of treatment. Such management is associated with a lower risk of VTE recurrence or hemorrhagic complications as compared with vitamin K antagonists (VKAs) [16] . Afterwards, the patient may be switched over to oral In a general population of patients with idiopathic PE, where it is not possible to identify the classical VTE risk factors, cancer will be diagnosed in up to 10% of the patients, over the first year of follow-up in most of the cases. However, extended diagnostics, including whole body imaging scans (PET, MRI, CT), does not result in a better prognosis in that group of patients. Hence, it
is not recommended to perform extended imaging diagnostics on a routine basis. Instead, what is promoted is in-depth clinical monitoring [19, 20] .
CONCLUSIONS
Cancer patients are exposed to an especially high risk of thromboembolic complications, which are usually associated with poor prognosis. Decisions on anticoagulation therapy, followed by anti-cancer treatment, require a case by case approach.
Ackowledgements

Authors of the paper would like to extend their thanks to all of the nurses and physicians in charge of the described patient. A special thank you goes to the team of the CMKP Department of Urology who carried out the surgery.
Recurrent pulmonary embolism in a patient with renal tumor J. Kępski, M. Kurzyna, S. Szmit
